What is first-line therapy for community-acquired pneumonia in healthy adults?
For previously healthy adult outpatients with CAP, guideline-based first-line therapy is a macrolide or doxycycline (if no antibiotics in the prior 3 months); those with recent antibiotic exposure, comorbidities, or moderate-severe disease requiring hospitalization are stepped up to a beta-lactam plus macrolide combination or a respiratory fluoroquinolone.
Outpatient treatment of previously healthy adults with CAP
- For previously healthy outpatients with CAP and no recent antibiotic exposure within 3 months, IDSA/ATS consensus guidelines recommend a macrolide or doxycycline as first-line therapy.
- In Canada and the United States, macrolides remain the recommended first-line therapy for outpatients with CAP but without comorbidities.
- For previously healthy patients who have had antibiotic therapy within the prior 3 months, guidelines recommend azithromycin or clarithromycin plus high-dose amoxicillin (4 g/day) or amoxicillin-clavulanate (4 g/day), or a respiratory fluoroquinolone alone.
Inpatient (non-ICU) treatment recommendations
- Based on ATS/IDSA and BTS/NICE CAP guidelines, combinations of beta-lactams and macrolides, or respiratory fluoroquinolones, are recommended as first-choice agents to treat empirically moderate-severe CAP in patients hospitalized on non-ICU wards.
Mild pneumococcal CAP in adults
- For community-acquired pneumonia in adults, macrolides (azithromycin, erythromycin or clarithromycin) or a respiratory fluoroquinolone (moxifloxacin, gemifloxacin or levofloxacin) are recommended for mild cases with susceptible organisms.
- In severe cases, ceftriaxone or cefotaxime are first-line agents, followed by vancomycin for life-threatening infection.
Sources
- JMM Profile: Streptococcus pneumoniae: sugar-coated captain of the men of death — Journal of Medical Microbiology
- Combination antibiotic therapy for community-acquired pneumonia — Annals of Intensive Care
- Third-generation cephalosporin use is frequently non-guideline-concordant in severe community-acquired pneumonia: Findings from a French critical care cohort — PLOS One
- Impact of Guideline Adherence on Outcomes in Patients Hospitalized with Community-Acquired Pneumonia (CAP) in Hungary: A Retrospective Observational Study — Antibiotics
- Country data on AMR in Saudi Arabia in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicine and clinical outcome — Journal of Antimicrobial Chemotherapy
- Comparison between diagnosis and treatment of community-acquired pneumonia in children in various medical centres across Europe with the United States, United Kingdom and the World Health Organization guidelines — Pneumonia
- Country data on AMR in Mexico in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicine and clinical outcome — Journal of Antimicrobial Chemotherapy
- Country data on AMR in Kuwait in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicine and clinical outcome — Journal of Antimicrobial Chemotherapy
Decision support for clinicians, not medical advice. Answers are grounded in the published literature and every claim cites its source in the interactive view.